Touch-down reverse transcriptase-PCR detection of IgVH rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia

Molecular Diagnosis

Volumn 9, Issue 1, 2005, Pages 23-34

  Peková, Soňa ^a,b   Marková, Jana ^a   Pajer, Petr ^b   Dvořák, Michal ^b   Cetkovský, Petr ^a   Schwarz, Jiří ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

DYE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; SYBR GREEN; UNCLASSIFIED DRUG; ORGANIC COMPOUND; RNA; SYBR GREEN I;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CALIBRATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COST CONTROL; FEMALE; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; PATIENT MONITORING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; CHEMISTRY; EVALUATION; GENETICS; IMMUNOGLOBULIN VARIABLE REGION;

FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; NEOPLASM, RESIDUAL; ORGANIC CHEMICALS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY;

EID: 26944442082     PISSN: 10848592     EISSN: 10848592     Source Type: Journal    
DOI: 10.2165/00066982-200509010-00004     Document Type: Article

References (42)

1. Rai KR, Sawitsky A, Jagathambal K, et al. Chronic lymphocytic leukemia. Med Clin North Am 1984; 68: 697-711
2. Dighiero G, Travade P, Chevret S, et al. B-cell chronic lymphocytic leukemia: present status and future directions. Blood 1991; 78: 1901-14
3. Molica S, De Rossi G, Luciani M, et al. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update. Haematologica 1995; 80: 176-93
4. Byrd JC, Waselenko JK, Keating M, et al. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol 2000; 27: 587-97
5. Hossfeld DK. Chronic lymphocytic leukaemia: risk-adapted therapy. Ann Oncol 2000; 11: 197-8
6. Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985-92
7. Rizouli V, Gribben JG. The role of stem cell transplantation in chronic lymphocytic leukemia. Semin Hematol 2004; 41: 246-53
8. Ferrarini M, Chiorazzi N. Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia. Semin Hematol 2004; 41: 207-23
9. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-34
10. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206
11. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-6
12. Ritgen M, Stilgenbauer S, Von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implication of minimal residual disease measurement with quantitative PCR. Blood 2004, Epub ahead of print
13. Rai KR, Döhner H, Keating MJ, et al. Chronic lymphocytic leukemia: case-based session. Hematology (Am Soc Hematol Educ Program) 2001, 156
14. H gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993-1007
15. H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-6
16. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-7
17. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-54
18. Brisco MJ, Tan LW, Orsborn AM, et al. Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population. Br J Haematol 1990; 75: 163-7
19. Voena C, Ladetto M, Astolfi M, et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793-8
20. Diss TC, Peng H, Wotherspoon AC, et al. Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type. J Pathol 1993; 169: 291-5
21. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052-7
22. Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003; 101: 2049-53
23. Bruggemann M, Pott C, Ritgen M, et al. Significance of minimal residual disease in lymphoid malignancies. Acta Haematol 2004; 112: 111-9
24. Pfitzner T, Engert A, Wittor H, et al. A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia. Leukemia 2000; 14: 754-66
25. Pfitzner T, Reiser M, Barth S, et al. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann Hematol 2002; 81: 258-66
26. Barragan E, Bolufer P, Moreno I, et al. Quantitative detection of AML1-ETO rearrangement by real-time RT-PCR using fluorescently labeled probes. Leuk Lymphoma 2001; 42: 747-56
27. Cassinat B, Zassadowski F, Balitrand N, et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000; 14: 324-8
28. Marcucci G, Caligiuri MA, Dohner H, et al. Quantification of CBFβ/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001; 15: 1072-80
29. Noy A, Verma R, Glenn M, et al. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. Blood 2001; 97: 1929-36
30. Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002; 100: 635-9
31. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-7
32. Catovsky D. Chronic lymphoid leukaemias. In: Hoffbrand AV, Lewis SM, Tud denham EGD, editors. Postgraduate haematology. 4th ed. Oxford: Butterworth-Heinemann, 1997: 405-33
33. H genes from different anatomical regions, with different histopathological patterns, of a rheumatoid arthritis patient suggest cyclic re-entry of mature synovial B-cells in the hypermutation process. Arthritis Res 2000; 2: 303-14
34. Sambrook J, Fritsh EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. New York: Cold Spring Harbor, 1989
35. National Center for Biotechnology Information. Igblast [online]. Available from URL: http://www.ncbi.nlm.nih.gov/igblast/ [Accessed 2004 Nov 29]
36. Jaksic O, Vrhovac R, Kusec R, et al. Clinical tumor cell distribution pattern is a prognostically relevant parameter in patients with B-cell chronic lymphocytic leukemia. Haematologica 2001; 86: 827-36
37. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102: 1515-25
38. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1625-38
39. Rassenti LZ, Kipps TJ. Lack of allelic exclusion in B cell chronic lymphocytic leukemia. J Exp Med 1997; 185: 1435-45
40. Magnac C, Sutton L, Cazin B, et al. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther 1999; 41: 13-8
41. Cabezudo E, Matutes E, Ramrattan M, et al. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 1997; 11: 1909-14
42. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-63